Novartis

News

Novartis knocked back again in bid to block Gilenya generics...

Novartis is running out of options in its bid to defend oral muscular sclerosis therapy Gilenya from early generic competition in the US.

News

Why does your address raise your risk of heart attack? AI se...

It's well known that where you live can have a profound impact on your risk of heart attack or stroke, but the exact reasons behind that inequality can be hard to tease out.

News

abstract shapes, bone structure, 3d render, bone

Sandoz takes aim at Amgen's Prolia/Xgeva with biosimilar

Novartis' soon-to-be-divested Sandoz unit has positive clinical trial data in hand for a biosi

News

Novartis nets potential blockbuster approval with sickle cel...

A new drug to treat painful episodes associated with sickle cell disease from Novartis is poised to hit the US market after approval from the FDA.

News

Novartis probed by Swiss authorities over 'unlawful' patent ...

The competition authorities in Switzerland said this morning they have carried out a raid on a pharma company – now confirmed to be Novartis – as part of an investigation into a "possible u

Oncology

Are radiopharmaceuticals the next breakthrough in oncology?

Ben Hargreaves examines what advantages radiopharmaceuticals offer in the treatment of cancer and why there has been interest from big pharma in developing these types of therapies.

Novartis knocked back again in bid to block Gilenya generics...

Why does your address raise your risk of heart attack? AI se...

Sandoz takes aim at Amgen's Prolia/Xgeva with biosimilar

Novartis nets potential blockbuster approval with sickle cel...

Novartis probed by Swiss authorities over 'unlawful' patent ...

Are radiopharmaceuticals the next breakthrough in oncology?

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Novartis

Editor's Picks